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Increasing the understanding of a proteome and how its protein composition is affected by for example
different diseases, such as cancer, has the potential to improve strategies for early diagnosis and
therapeutics. The Global Proteome Survey or GPS is a method that combines mass spectrometry and
affinity enrichment with the use of antibodies. The technology enables profiling of complex proteomes
in a species independent manner. The sensitivity of GPS, and other methods relying on affinity
enrichment, is largely affected by the activity of the exploited affinity reagent. We here present an
improvement of the GPS platform by utilizing an antibody immobilization approach which ensures a
controlled immobilization process of the antibody to the magnetic bead support. More specifically, we
make use of an antibody format that enables site-directed biotinylation and use this in combination with
streptavidin coated magnetic beads. The performance of the expanded GPS platform was evaluated by
profiling yeast proteome samples. We demonstrate that the oriented antibody immobilization strategy
increases the ability of the GPS platform and results in larger fraction of functional antibodies.
Additionally, we show that this new antibody format enabled in-solution capture, i.e. immobilization of
the antibodies after sample incubation. A workflow has been established that permit the use of an
oriented immobilization strategy for the GPS platform.Introduction
The proteome is a snapshot of the protein composition of a specific
sample type present at a certain state and time point. Investigation
of the human proteome in well established samples has the
possibility to increase our understanding of different human dis-
eases, such as cancer, and contribute to the development of
approaches for early diagnosis and therapeutics [1,2]. The bio-
marker discovery phase has for a long time mainly been carried out
by standard mass spectrometry (MS) technologies [3], but very few
candidate biomarkers have been transformed into clinical use
[4,5]. This suggests that there is a need for better technologiesCorresponding author: Borrebaeck, Carl A.K. (Carl.Borrebaeck@immun.lth.se),
Wingren, C. (Christer.Wingren@immun.lth.se)
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1871-6784/ 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-Nboth concerning the discovery phase and for validation of identi-
fied biomarkers. Some of the difficulties in MS have been associat-
ed with assay sensitivity and reproducibility as well as with sample
complexity in regards to the large dynamic range of proteins [6,7].
MS and antibody based technologies both have distinct advan-
tages and disadvantages. Different approaches have therefore been
made into combining MS and affinity enrichment with the use of
antibodies [3,8–12].
We have previously described a method for profiling complex
proteomes in a species independent manner denoted Global Prote-
ome Survey or GPS [11,13–15] in a way that combines the power of
MS and antibody technology. GPS explores single chain antibodies
(scFv) directed against short peptide motifs and MS. As illustrated
in Fig. 1 (left panel), the general workflow of GPS involves fivewww.elsevier.com/locate/nbt
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 503
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FIGURE 1
Schematic outline of the three different capture versions evaluated for the GPS platform. In capture 1, the CIMS scFvs are chemically coupled to magnetic beads. In
capture 2, biotinylated CIMS scFvs are coupled in an oriented manner to streptavidin magnetic beads. In capture 3, the biotinylated CIMS scFvs are allowed to bind
tryptic peptides before coupling to streptavidin magnetic beads.
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magnetic beads, (ii) incubation with tryptic digest, (iii) washing, (iv)
elution of bound peptides and (v) detection of eluted peptides by
shot-gun MS. One of the powers of GPS lays in its ability to target a
large number of proteins with the use of a small number of scFv
antibodies. In affinity proteomics approaches the one to one rela-
tionship between the protein of interest and its targeting affinity
probe is a large technology bottleneck. Not only must the target of
interest be known in advance but there is a lack of availability of
these specific reagents as well as a very substantial requirement in
the specificity of the affinity probes. In GPS the scFv antibodies,
termed context independent motif specific (CIMS) antibodies, are
directed towards sets of short peptide fragments present in up to a
few hundreds of proteins. More specifically, the CIMS scFvs targets
4–6 amino acid long C-terminal sequence motifs of tryptic peptides
and are termed context independent since they enables analysis of
any proteome regardless of species. This means that the GPS plat-
form holds great potential in targeting any proteome in a discovery
directed manner. Theoretically, the use of about 100 of these CIMS504 www.elsevier.com/locate/nbtscFvs would cover 50% of the nonredundant human proteome
[11,16]. The GPS platform has recently been used to characterize
breast cancer tissue samples and it has successfully described protein
signatures correlated to histological grades of breast cancer [15].
In immunoassays, maintaining the biological activity of the
antibody during immobilization is of great importance [17,18].
The sensitivity of the assay is to a large extent influenced by the
orientation of the antibody as well as the surface density of the
immobilized antibody onto the solid-support [17]. By orienting
the antibody on the surface, the antigen binding sites are exposed
and the accessibility to the antigen is increased [19]. Consequent-
ly, a key step in GPS is the immobilization of the CIMS scFvs onto
paramagnetic particles that are used to capture peptides from
complex samples. This has previously been achieved by conven-
tional chemical covalent coupling of the CIMS scFvs to activated
carboxylic acid groups on the magnetic beads [11]. Here we have
further advanced the GPS platform by adding a second approach of
antibody immobilization. A system is used that provides the CIMS
scFvs with an biotin acceptor domain (BAD) [20,21]. This enables
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and further on immobilization in an oriented manner on strepta-
vidin magnetic beads.
The different versions of the GPS platform exploiting both chem-
ically coupled and tag-oriented scFv were used for profiling yeast
cell lysate samples in a parallel manner to compare how the immo-
bilization of the CIMS scFv affects the peptide capture ability of
the platform. Furthermore, the possibility of performing immobili-
zation of the CIMS scFvs after peptide capture was evaluated.
Experimental procedures
CIMS antibodies
The human recombinant scFv antibodies CIMS17-C08, CIMS17-
E02 and CIMS33-3D-F06 had been selected from the phage display
library, n-CoDeR [22], as previously described [11]. These three
CIMS scFv were included based on good performance in previously
performed GPS capture investigations. CIMS17-C08 and CIMS17-
E02 were developed against target peptide motif 17 (amino acid
sequence: SSAYSR) and CIMS33-3D-F06 against target peptide
motif 33 (amino acid sequence: LSADHR).
Production and purification of soluble CIMS antibody fragments
The three scFv were produced in 15 ml Escherichia coli cultures.
Briefly, 15 ml TB medium (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) supplemented with 0.2 M sucrose and
100 mg/ml carbenicillin (Saveen & Werner AB, Sweden) was used
for production. ScFv production was induced with the use of 1 mM
isopropyl thiogalactioside (IPTG). Cultures were grown over night
at 308C. Bacteria were harvested by centrifugation and scFvs were
purified from the periplasmic space with MagneHisTM Protein
Purification System (Promega Corporation, Madison, WI, USA)
with the use of a KingFisher Flex robot. Both the purity and
integrity of the scFvs were verified with SDS–PAGE.
Production and purification of soluble biotinylated CIMS
antibody fragments
A vector format (pHP2-19) [23] that allows for the production of
the scFvs with a biotin acceptor domain (BAD) preceding the
hexahistidine tag at the C-terminus was used for production
and purification of a biotinylated version of the scFvs. The DNA
encoding each scFv was digested with SfiI and AvrII (New England
Biolabs, Ipswich, MA, USA) according to manufacture’s instruc-
tions and re-ligated into the pHP2-19 vector and transformed into
AVB101 (Avidity LLC, Aurora, CO, USA), an E. coli B strain contain-
ing pBirAcm, encoding biotin ligase (BirA) and chloramphenicol
resistance (Avidity LLC). Biotinylated soluble scFvs were produced
and purified as described above with the exception that 10 mg/ml
chloramphenicol (Saveen & Werner AB) was also added and that a
final concentration of 1.5 mM of IPTG together with 50 mM biotin
was used.
Functionality assay of CIMS antibodies
The functionality of the scFvs in the two different vector formats
was evaluated against respective target peptide (JPT Peptide Tech-
nologies GmbH, Berlin, Germany) used for development of the
scFvs in ELISA. Streptavidin were immobilized at a concentration
of 1 mg/ml in 384-well plates (Corning Inc., New York, NY, USA)
and incubated over night at 48C. Unbound protein was removedby washing the plate once with 154 mM NaCl and 0.05% (v/v)
Tween 20 (wash buffer). Biotinylated peptides (biotin-
SGSGSSAYSR and biotin-SGSGLSADHR) were added at a concen-
tration of 1 mg/ml in PBS. The plate was incubated for 1 h at room
temperature (RT) with mixing and then washed with wash buffer
four times. The plates were blocked with 0.5% (w/v) bovine serum
albumin (BSA) and 0.05% (v/v) Tween 20 in PBS (PBT) containing
2 mg/ml free biotin for 40 minutes at RT with mixing. After four
washing steps with wash buffer, purified scFvs were added and
incubated with target antigen for 2 h at RT with shake. Once again
the plate was washed four times followed by addition of horserad-
ish peroxide (HRP)-labelled streptavidin (Thermo Scientific Pierce,
Rockford, IL, USA) or HRP-labelled anti-His6 monoclonal antibody
(Roche Diagnostics GmbH, Mannheim, Germany) in PBT and
incubated for 1 h at RT with mixing. Bound scFv were, after
washing, detected with the use of TMB-ELISA (Thermo Scientific
Pierce) as chromogen. The reaction was stopped with sulfuric acid
(1 M) and the absorbance was measured at 450 nM.
Preparation of trypsin digested yeast proteome
Whole-cell protein extract from Saccharomyces cerevisiae (Promega
Coporation) (1 mg) was reduced, alkylated and digested with
trypsin. After thawing the protein extract at RT the sample was
reduced with DTT (Saveen & Werner AB), at a final concentration
of 5 mM, during 30 minutes at 378C. Subsequently, the sample was
alkylated for 30 minutes in the dark at RT with iodoacetamide
(Sigma-Aldrich Corp., St. Louis, MO, USA) at a final concentration
of 15 mM. Finally, sequenced-grade modified trypsin (Promega
Corporation) was added at 20 mg per mg of protein and incubated
for 16 h at 378C. Next, the samples were aliquoted and stored at
808C until use.
Coupling of magnetic beads
Two different bead systems were used for coupling of the purified
scFvs: Dynabeads M-270 Carboxylic acid and Dynabeads M-270
Streptavidin (Invitrogen Dynal AS, Oslo, Norway). The purified
scFvs were coupled individually to the magnetic beads and used for
GPS capture experiment. For Dynabeads M-270 Carboxylic acid,
25 mg scFv were coupled per 1 mg beads as previously described
[11]. Briefly, 300 ml of beads (9 mg) were washed twice in 25 mM
MES buffer (pH 6) with slow mixing for 10 minutes. The beads
were activated with 25 mg/ml EDC (Sigma) and 47 mg/ml Sulfo-
NHS (Thermo Scientific) with slow mixing for 30 minutes. After
washing once with 25 mM MES and PBS respectively, scFvs were
added to the beads and incubated for 45 minutes at RT with gentle
mixing. The coated beads were washed twice with 50 mM Tris (pH
7.4) to block the uncoupled surface. Afterwards, the beads were
washed a total of four times with 0.05% (v/v) Tween 20 in PBS (TPBS)
and finally resuspended in TPBS and stored at 4 8C until further
use. For Dynabeads M-270 Streptavidin, 10 mg of biotinylated scFv
were coupled per 1 mg beads. Briefly, the beads were washed twice
with PBS, then mixed with biotinylated scFv in PBS and incubated
for 45 minutes with mixing at RT. The beads were washed once
and resuspended in TPBS and stored at 48C until further use.
GPS capture experiment
Three different capture experiments were performed, with scFv
chemically coupled to beads, with biotinylated scFv coupled towww.elsevier.com/locate/nbt 505
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streptavidin coated beads after capture (Fig. 1). The tryptic yeast
proteome sample was defrosted and 1 mM phenylmethylsulfonyl
(PMSF) were added to inhibit trypsin activity. For each capture,
35 ml beads with immobilized scFv, either with scFv chemically
coupled or coupled via biotin–streptavidin, were used. The cou-
pled beads were washed in TPBS and 35 ml of tryptic yeast sample
(20 mg) was added. The mixture was incubated for 15 minutes at
RT with gentle hand mixing every two minutes. After incubation,
the beads were washed first with 65 ml PBS and then with 50 ml PBS
and transferred to a new tube. Captured peptides were eluted by
adding 8.5 ml 5% (v/v) formic acid and subsequently transferred to
a new tube. The samples were dried and frozen at 208C until
analysis. Before analysis, the samples were reconstituted in 8 ml
0.1% (v/v) formic acid, 3% (v/v) acetonitrile and transferred to
HPLC vials. For the in-solution capture, the capture was performed
as described above with the exception that uncoupled biotinylated
scFvs were mixed with the tryptic yeast sample before coupling
onto beads. After 15 minutes of incubation, pre-washed
uncoupled beads were added to the scFv peptide mixture and
coupling of scFv onto beads were allowed to proceed for 45–
60 minutes. The samples were then prepared as described above.
Mass spectrometry analysis
Captured peptides were analyzed on ESI-LTQ-Orbitrap (Thermo
Electron, Bremen, Germany) coupled to an Eksigent two-dimen-
sional nano HPLC (Eksigent technologies, Dublin, CA). With the
use of auto-sampler 6 ml of sample was injected. The peptides were
trapped on a pre-column (PepMap 100 C18, 5 mm  0.3 mm,
5 mm LC Packings, Amsterdam, Netherlands) and separated on a
reversed-phase analytical column (10 mm fused silica emitter,
75 mm  16 cm (PicoTip Emitter, New Objective, Inc., Woburn,
MA, USA) packed in-house with Reprosil-Pur C18-QA resin (3 mm,
Dr.Maisch Gmbh, Ammerbuch-Entringen, Germany)). The pep-
tides were loaded onto the pre-column at a flow rate of 10 ml/min
for 15 min and separated on the reversed-phase analytical column
at a flow rate of 300 nl/min using a 45 min linear gradient of 3–
35% (v/v) acetonitrile in water containing 0.1% (v/v) formic acid.
Solvent A consisted of 0.1% (v/v) formic acid in water and solvent
B consisted of 0.1% (v/v) formic acid in acetonitrile. The total run
time including washing and equilibration of column was 120 min.
The LTQ-Orbitrap was operated in a data-dependent mode to
automatically switch between Orbitrap-MS and LTQ-MS/MS ac-
quisition. Four MS/MS spectra were acquired using CID (at 35%
normalized collision energy) in the LTQ and each Orbitrap-MS
scan was acquired at 60 000 FWHM nominal resolution setting
using the lock mass option (m/z 445.120025) for internal calibra-
tion.
Data analysis
The generated data was analyzed using the Proteios SE for gener-
ating identifications both using Mascot and X!Tandem. All data
was processed in Proteios SE [24], and processed in a label free
workflow [25]. Raw data files were converted to mzML and MGF
using Proteowizard. Searches were performed against all Saccha-
romyces cerevisiae proteins in SwissProt as of 20150506 expanded
for isoforms, supplemented with an equal number of decoy pro-
teins (reverse sequence), totaling 13 480 sequences. The following506 www.elsevier.com/locate/nbtsearch parameters were used: enzyme trypsin, missed cleavage 1,
fixed modification carbamidomethyl (C), variable modification
methionine oxidation (O). A peptide mass tolerance of 5 ppm
and fragment mass tolerance of 0.4 Da was used. Peptide identi-
fications were generated by the automated database searches in
both Mascot and X!Tandem and a combination were used with a
false discovery rate (FDR) of 0.01. The identified peptides for all
samples were used for creating binding profiles with the use of the
tool WebLogo (v. 2.8.2) [26]. The reproducibility and peptide
overlap between different replicates were analyzed with the use
of Venn diagrams created by BioVenn [27].
FACS analysis
The coupled magnetic beads for both coupling systems, scFvs
chemically coupled to M-270 carboxylic acid magnetic beads
and biotinylated scFvs coupled to M-270 streptavidin magnetic
beads, were analyzed in flow cytometry experiments to evaluate if
scFvs had been successfully coupled to the surface. ScFvs coupled
onto magnetic surface were detected with a mouse anti-His anti-
body (R&D systems, Minneapolis, MN, USA). A goat anti-mouse
antibody conjugated with APC fluorochrome (BD Bioscience, San
Jose, CA, USA) was used for detecting the bound anti-His antibody.
For the analysis, 150 mg M-270 carboxylic acid beads and 50 mg M-
270 streptavidin magnetic beads carrying scFv were incubated
with anti-His antibody at different concentrations for about 1 h
at RT. The beads were washed twice with TPBS before addition of
the anti-mouse-APC secondary antibody. To evaluate the extent of
activity of the coupled scFvs, beads were incubated for 1 h at RT
with biotinylated peptides complexed to Alexa 647-labelled strep-
tavidin (Thermo Fisher Scientific) (3:1 molar ratio) or only strep-
tavidin conjugated Alexa-647 were included in the analysis. Flow
cytometry analysis was performed with BD FACSCanto II (BD
Bioscience) cell analyzer.
Results
Peptide capture and identification
In the GPS platform, the combination of CIMS scFvs directed
against short peptide motifs and shot-gun MS allows for investi-
gation of complex proteomes in a discovery oriented mode. In this
study, a side-by-side comparison between three different versions
of the GPS platform was performed using three different CIMS scFv
and by analysis of a trypsin digested yeast (S. cerevisiae) sample. The
digested protein sample was exposed to either immobilized or
non-immobilized CIMS scFvs and the affinity enriched tryptic
peptides were identified with the use of LC–MS/MS analysis.
Figure 1 outlines the three different capture types. GPS capture
1 corresponds to the previously used version of the GPS platform
[11], using CIMS scFvs chemically coupled to magnetic beads. GPS
capture 2 exploits site-specific biotinylated CIMS scFvs coupled to
streptavidin coated magnetic beads, a method that should result in
a more controlled orientation of the attached scFvs. GPS capture 3
corresponds to the platform version were uncoupled biotinylated
CIMS scFvs are first incubated with the tryptic peptides prior to
immobilization onto streptavidin magnetic beads (in-solution
capture). The MS based peptide identification was performed in
the same way in all cases.
For all three included CIMS scFvs it could be observed that
capture version 2 of the GPS platform, using scFv coupled through
New Biotechnology Volume 33, Number 5  September 2016 RESEARCH PAPER
TABLE 1
The total number of detected peptides and the number of unique
detected peptides for all replicate captures for the three different
scFv capture system combinations.
scFv Capture
version
Experiment Total number
of detected
peptides
Number of
unique
detected
peptides
CIMS17-C08 Capture 1 1 4 3
2 18 13
3 12 8
Capture 2 1 628 335
2 846 432
3 906 461
Capture 3 1 38 28
2 6 4
3 15 10
CIMS17-E02 Capture 1 1 9 7
2 3 2
3 3 2
Capture 2 1 774 375
2 1008 481
3 1017 487
Capture 3 1 530 276
2 439 230
3 562 307
CIMS33-3D-F06 Capture 1 1 2 1
2 4 3
3 4 3
Capture 2 1 228 131
2 126 65
3 521 285
Capture 3 1 94 60
2 132 77
3 107 69
Negative
control
Capture 1 1 0 0
2 1 1
3 0 0
Capture 2 1 0 0
2 0 0
3 0 0
Capture 3 1 1 1
2 0 0
3 3 2
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uniquely detected peptides (Table 1). The CIMS17-E02 antibody
showed the best performance with around 400 unique identified
peptides in the oriented immobilization strategy of the platform
(capture version 2). One of the problems with traditional MS
methods have been low reproducibility and the stochastic nature
of the data sampling contributes to that the expected reproduc-
ibility of identified peptides in different LC–MS/MS runs is be-
tween 35 and 50% [28]. The GPS platform with an oriented
coupling strategy (capture 2) showed a good repeatability with
an overall peptide overlap between replicates in several cases close
to 50% (Figure S2). The chemically coupling immobilization strat-
egy (capture 1) resulted in a substantially lower number of identi-
fied peptides for all included CIMS scFvs (Table 1). Capture version
3 of the platform also performed well for two of the included CIMS
scFvs, in particular for CIMS17-E02. This demonstrates the poten-
tial for further expansion of the GPS platform approach and thepossibility of using this capture format when relevant. Capture
experiments performed with beads not carrying immobilized
CIMS scFvs resulted in a very low number of captured peptides
(Table 1). This indicates that the platform had a very low degree of
background and that the identified peptides were a result of the
affinity enrichment achieved with the included CIMS scFvs. Re-
garding the negative control samples for the chemically coupling
immobilization strategy (capture 1), only one peptide was identi-
fied for one of the replicates. This implied that even though these
capture experiments resulted in a low number of identified pep-
tides, the identified peptides were actual identifications and not
due to the background of the system.
To ensure that the lower degree of performance of the CIMS
scFvs coupled through chemical activation was not a result of an
unsuccessful coupling of the antibodies to the magnetic beads,
flow cytometry experiments were performed on the coupled beads
included in the different capture 1 and capture 2 type experiments.
With the use of an anti hexahistidine tag specific monoclonal
mouse antibody, CIMS scFvs coupled to both bead systems were
identified (Fig. 2). Analysis of binding to biotinylated peptide/
streptavidin conjugates demonstrated that CIMS scFvs chemically
coupled to beads showed poor binding activity towards their target
peptides, while the CIMS scFvs coupled through the biotinylated
BAD show good binding activity (Fig. 3). In sharp contrast and as
illustrated in supplementary Figure 1, ELISA data show specific
binding to intended target peptide for all three CIMS scFvs used for
chemical coupling (panel a, c and e) prior immobilization. This is
also true for the biotinylated versions of the same CIMS scFvs
(panel b, d and f). We therefore conclude that the lower perfor-
mance of the chemically coupled CIMS scFvs is a result of the
immobilization method used.
Binding profile and length analysis
To further assess the performance of the different GPS platform
variants (Fig. 1), we also evaluated the peptide binding motifs for
the CIMS scFvs included in the investigation (Fig. 4). It has
previously been established that the CIMS scFvs bind peptides
with a certain binding motif [14]. It was pin-pointed that the last
four C-terminal amino acid residues were important for binding
and that 2 to 3 positions were more conserved and acted as anchor-
positions for the peptide binding. It could once again be conclud-
ed that the CIMS scFvs individually expressed specific binding
patterns (Fig. 4). The established binding profiles correlated very
well with the previously determined motifs. The third last and last
residue (denoted 4 and 6) seemed crucial for binding and could
again be identified as anchor-positions while a large variation was
allowed for the remaining positions. As seen in Fig. 4, the identi-
fied binding motifs are largely consistent regardless of the immo-
bilization strategy or for the capture format used for each
respective CIMS scFv. The agreement in binding profile is kept
intact although a much lower number of peptides were identified
for capture version 1 of the GPS platform. Indeed the majority of
the identified peptides contain the specific binding profile (Table
2). Although the predominant peptide motif was conserved be-
tween different capture approaches, it is conceivable that other
parts of the binding site contribute to peptide binding beyond the
core of the binding site [29,30]. The composition of the enriched
peptide pool may be effected in other ways. We therefore alsowww.elsevier.com/locate/nbt 507
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FIGURE 2
Flow cytometry detection of CIMS scFv coupled to beads using an anti-His antibody. CIMS scFv CIMS17-C08 (a,b), CIMS17-E02 (c,d) and CIMS33-3D-F06 (e,f) were
bound to magnetic beads by chemical coupling (a, c, e) or via biotin–streptavidin (b, d, f ).
TABLE 2
The number of detected peptides without main binding profile for the oriented capture system. Previously determined binding profiles
for the included CIMS scFvs were used to evaluate the amount of unique peptides identified in this capture experiment that did not
contain the same binding motifs.
scFv Selection target peptide Capture version Binding profile Experiment Frequency of peptides lacking
main binding profile
CIMS17-C08 SSAYSR Capture 2 X X X F/Y/W X R All replicates 75/554
1 33/335
2 50/432
3 55/461
CIMS17-E02 SSAYSR Capture 2 X X X Y X R/K All replicates 135/610
1 55/375
2 98/481
3 96/487
CIMS33-3D-F06 LSADHR Capture 2 X X X D X R/K All replicates 94/299
1 39/131
2 8/65
3 88/285
508 www.elsevier.com/locate/nbt
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FIGURE 3
Flow cytometry detection of peptide binding to scFv coupled beads. CIMS scFv CIMS17-C08 (a,b), CIMS17-E02 (c,d) and CIMS33-3D-F06 (e,f) were bound to
magnetic beads by chemical coupling (a, c, e) or via biotin–streptavidin (b, d, f ). Detection reagents included Streptavidin-Alexa-647 alone (top panel), an
irrelevant biotinylated peptide bound to Streptavidin-Alexa-647 (mid panel) and biontinylated peptide used for CIMS scFv development bound to Streptavidin-
Alexa-647 (lower panel).
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marker for peptide character (Fig. 5). The low number of peptides
identified after use of capture version 1 precludes efficient assess-
ment of this parameter. Peptides collected by capture version 2 and
3 demonstrate similar length profiles (Fig. 5). The number ofpeptides without the binding motif varies between the different
CIMS scFvs but the number of peptides without the predominant
binding motif does not exceed 30%.
Overall, the identified peptides for respective CIMS scFv anti-
body correlate well in both binding pattern and length to whatwww.elsevier.com/locate/nbt 509
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FIGURE 4
Binding profiles detected for the three different scFvs in all capture formats.
The binding profiles created at WebLogos include all unique peptides
identified in all replicates for respective CIMS scFv and capture system.
510 www.elsevier.com/locate/nbt
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platform [14]. It can be concluded that the detected peptides do
not vary much in either binding motif or length regardless of how
the GPS platform is performed.
Discussion
Affinity proteomics, such as antibody microarrays, have become
an important contributor to the discovery phase of biomarker
identification for different complex proteomes and sample for-
mats [31–37]. However, drawbacks involve the need of a priori
known target proteins. The technology’s ability to detect new
targets is thereby diminished. Traditional MS techniques with
classical fractionation methods have had problems with reproduc-
ibility and are less convenient for analysis of large sample cohorts
or of analytes present at low concentrations in complex samples
[38–40]. The GPS technology combines the strength of antibody
technology and MS and has shown great promise for proteomic
discovery studies with regards to quantitative capability, repro-
ducibility and sensitivity [13]. The methodology offers possibilities
in profiling complex proteomes in a specie independent discovery-
directed fashion.
In this study, we have further developed the standard GPS
platform by introducing a second strategy for immobilization of
the peptide-enriching affinity reagents, the CIMS scFvs, exploited
in GPS. Previously, the CIMS scFvs have been immobilized with
the use of chemical covalent coupling in a non-oriented fashion.
Here, biotinylation of a tag on the CIMS scFvs were employed for
coupling in an oriented manner to streptavidin magnetic beads.
This tag is located far away from the antigen binding site of the
scFvs, guaranteeing that the antigen binding site of the CIMS scFv
is exposed to the surrounding when immobilized. Other platforms
combining affinity enrichment and MS, such as SISCAPA and TXP,
have mostly utilized monoclonal or polyclonal full-length anti-
bodies for the enrichment target peptides [8,41–43]. However,
recombinant antibody fragments, e.g. Fabs, have also been shown
to be applicable affinity reagents [44]. Here protein G or specific
tag-sequences have been employed to ensure the orientation of
the utilized antibody or antibody fragment. In all immunoaffinity
based systems the activity of the affinity probe, such as an anti-
body or antibody fragment, highly influences the functionality
and sensitivity of the system. The activity of an antibody is closely
related to its structure and the integrity of its antigen binding site.
There is always a risk that the immobilization procedure of the
antibody affects the structure of the antibody and thereby its
activity. Covalent immobilization strategies via free amine groups
on the scFv entail a coupling procedure that can affect the antigen
binding site and the activity of the antibody. Such effects depend
on the positions of the functional groups used for the attachment
and by the sequence of the antibody at hand. The procedure can
both affect the antigen binding site and denature the antibody as a
result of the strain introduced from multiple attachment sites as
well as by steric hindrance caused by neighboring antibodies [45].
There can also be problems with batch to batch variations between
different coupling batches as a consequence of the randomness of
the coupling event. When instead utilizing an oriented coupling
strategy, as for example via biotin–streptavidin, the coupling
procedure can be better controlled. However, the biotinylation
procedure of the antibody also needs to be considered. Chemical
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FIGURE 5
Peptide lengths profiles representing unique peptides for each CIMS scFv capture system combination. The detected median length for CIMS17-C08 was 10, 11,
and 11 amino acids for non-oriented (capture 1), oriented (capture 2) and in-solution strategies (capture 3). For CIMS-E02 respective median lengths were 8, 13,
and 13 amino acids, and for CIMS33-3D-F06 the respective median lengths were 9, 12, and 13 amino acids.
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lysines) is random. It can in the same way as the non-oriented
immobilization procedure affect the activity and conformation of
the antibody [46,47] and is prone to batch-to-batch variability.
Site-specific biotinylation is therefore preferred and may be per-
formed with different methods [20,21,48,49]. Here we use site-
specific biotinylation, via the use of a biotin acceptor domain
(BAD) and biotin ligase BirA, of the CIMS scFvs. Neither the
biotinylation nor the coupling procedure via streptavidin magnet-
ic beads should affect the activity of the scFvs to a great extent. It
was confirmed with ELISA (Figure S1) that the biotinylation pro-
cess of the scFvs do not extensively effect their activity towards the
peptide used for antibody development. The use of site-specific
biotinylation of the CIMS scFvs and an oriented attachment
strategy with streptavidin magnetic beads offers a high control
over the immobilization procedure and likely a minimal effect on
antigen binding sites.
To assess the influence of a directed and controlled immobili-
zation method with minimal effect on the paratope of the CIMS
scFv, three different GPS systems were evaluated against a tryptic
yeast proteome. It was concluded that the oriented GPS platform(capture 2) exploiting biotinylated scFv performed better com-
pared to the non-oriented chemically coupled system (capture 1)
as shown by the number of identified peptides. In our view this is
the consequence of a substantially better activity of CIMS scFv
coupled via biotin to the magnetic beads and not to an unsuccess-
ful coupling in terms of problems with the actual immobilization
process. Importantly, the platform version utilizing biotinylated
scFv has a good reproducibility despite of the stochastic detection
of peptides in the data sampling.
The CIMS scFv antibodies in the GPS platform are directed
towards short tryptic motifs. Olsson et al. previously determined
that certain positions within the binding motif act as anchor
positions and are very important for antigen binding while a
much larger variation is allowed in the remaining positions
[14]. The same properties could be identified for the CIMS scFvs
in this study irrespective of the capture approach. Hence, we could
conclude that the capture approach does not effect the model of
how the CIMS scFvs capture respective sets of target peptides but
rather influences the performance of the capture.
Overall, we have enhanced our GPS platform by adding a
second strategy for immobilization of the CIMS scFvs forwww.elsevier.com/locate/nbt 511
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erimproved peptide capture performance. The new approach utilizes
site-directed biotinylation of the CIMS scFvs and further on im-
mobilization to streptavidin magnetic beads. This ensures an
oriented coupling procedure and a much higher activity and
capacity of the immobilized CIMS scFvs and the GPS platform.
The new immobilization strategy also allows for the GPS platform
to be used for in-solution captures, were the CIMS scFv are not
coupled to beads until after capture, which further expands the
applicability of the system.
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